Precision Immuno-Oncology Market: Competitive Intelligence Report with Key Players and Strategies

Spread the love

Introduction to the Global Precision Immuno-Oncology Market

The Global Precision Immuno-Oncology Market, valued at USD 51.20 billion in 2022, anticipates robust growth, projecting a remarkable CAGR of 9.90% through 2028, as per the TechSci Research report titled “Global Precision Immuno-Oncology Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028.” This growth trajectory is attributed to strategic collaborations among industry leaders, amalgamating diverse expertise to fortify market positions.

Driving Forces of Market Growth

Role of Genomic and Molecular Profiling

Genomic and molecular profiling techniques, notably next-generation sequencing (NGS), play a pivotal role in identifying specific genetic mutations and alterations within tumor cells. This information is vital in discerning the tumor’s targetable mutations, aiding in the selection of precision immuno-oncology treatments. Profiling predicts a patient’s response likelihood to immunotherapy based on factors such as tumor mutational burden (TMB) or specific genetic markers. It facilitates the identification of synergies between different therapies, enabling clinicians to determine effective treatment combinations. Moreover, these techniques contribute to expediting the development of new treatments by matching patients with relevant clinical trials, broadening the spectrum of available treatment options.

Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on ” Precision Immuno-Oncology Market.” – https://www.techsciresearch.com/report/precision-immuno-oncology-market/19558.html

Role of Precision Immuno-Oncology in Minimizing Overtreatment

Precision immuno-oncology endeavors to curtail overtreatment by avoiding therapies with limited effectiveness, reducing unnecessary side effects, and enhancing patients’ quality of life. Close monitoring of patients’ responses during treatment allows for adaptive modifications based on ongoing genomic and immune profiling. This adaptive approach ensures timely alterations in treatment plans if resistance or disease progression is detected.

Strategic Partnerships and Market Developments

Case Study: Ipsen and Marengo Therapeutics, Inc. Collaboration

In August 2022, Ipsen and Marengo Therapeutics, Inc. united in a strategic partnership aiming to advance two preclinical candidates generated through Marengo’s STAR platform into clinical trials. Marengo’s Selective T Cell Activation Repertoire (STAR) platform, distinguished by its ability to modulate T cell responses within specific subsets, presents a promising mechanism in T cell activation. Ipsen’s global presence in oncology aligns with Marengo’s innovative research capabilities, focusing on potent T cell activators that target distinct TCR Vβ variants.

Challenges in the Global Precision Immuno-Oncology Market

Limited Patient Eligibility

Patient eligibility poses a significant challenge in precision immuno-oncology due to reliance on specific biomarkers like PD-L1 expression, tumor mutational burden (TMB), or specific genetic mutations. Patients lacking these relevant biomarkers may not qualify for targeted or immunotherapeutic treatments. Tumor heterogeneity, where different tumor regions possess distinct genetic profiles, complicates biomarker assessments, potentially leading to inaccurate eligibility determinations. Rarity of certain biomarkers restricts the pool of eligible patients for targeted therapies or clinical trials.

Market Segmentation and Biomarker Significance

Segmentation Based on Biomarkers

The Global Precision Immuno-Oncology Market segments into biomarkers such as PD-L1, BRCA, KRAS, EGFR, and others. EGFR (Epidermal Growth Factor Receptor), a pivotal protein found on certain cells, plays a crucial role in cell growth and division. Alterations in the EGFR gene or protein relate to cancer development and are diagnostic biomarkers used in various cancers, including lung cancer, colorectal cancer, and specific brain tumors.

Regional Analysis: North America

North America dominates the Global Precision Immuno-Oncology Market, leveraging extensive healthcare databases and patient repositories for personalized treatment approaches. The region’s inclination toward adopting innovative medical technologies, openness among physicians to integrate new treatments, and the presence of major pharmaceutical companies drive advancements in precision immuno-oncology. Patient demand for advanced cancer treatments and active participation in clinical trials contribute to North America’s leadership in this market.

Who Will Benefit from This Report?

Healthcare providers seeking insights into precision immuno-oncology advancements and personalized treatment approaches.
Pharmaceutical companies aiming to understand market trends, biomarker significance, and innovative therapy development.
Patients and advocacy groups seeking awareness and access to personalized immuno-oncology treatments.
Investors and stakeholders exploring growth prospects and potential collaborations within the precision immuno-oncology sector.
Researchers and academia interested in contributing to the development of diagnostic tools and innovative therapies in immuno-oncology.

This detailed report provides comprehensive insights into the Global Precision Immuno-Oncology Market, encompassing market drivers, collaborative strategies, challenges, biomarker significance, regional dynamics, and the diverse spectrum of beneficiaries seeking to navigate and contribute to the evolving landscape of precision oncology.

Some of the major companies operating in the Global Precision Immuno-Oncology Market include:

Adaptimmune Therapeutics Plc
Agenus Inc.
Amgen Inc
AstraZeneca plc
Bristol Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
Hoffmann-La Roche Ltd.
Gilead Sciences, Inc
GlaxoSmithKline Plc

“Certain areas, particularly in North America, are projected to exert significant demand for precision immune oncology. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhance the overall wellbeing of people each year, are expected to contribute to a remarkable growth of the Global Precision Immuno-Oncology Market in the forecast period,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based Global management consulting firm.

Precision Immuno-Oncology Market By Cancer type (Lung cancer, Breast cancer, Prostate cancer, Melanoma, and others), By Treatment type (Checkpoint Inhibitors, Car T cell Therapy, Cancer Vaccines, and others), By Biomarker (PD-L1, BRCA, KRAS, EGFR, and others), By End-user (Hospital & Clinics, Research Institutes, others), By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Global Precision Immuno-Oncology Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Precision Immuno-Oncology Market.

Download Free Sample Report – https://www.techsciresearch.com/sample-report.aspx?cid=19558

Recently Published Report –

Precision Immuno-Oncology Market

Brain Imaging and Neuroimaging Market

Bunion Correction Systems Market

Amyotrophic Lateral Sclerosis (ALS) Market

DNA Amplification Kit Market

Carcinoid Syndrome Diarrhea Treatment Market

Attention Deficit Hyperactivity Disorder (ADHD) Market

Contact Techsci Research–

US –

Mr. Ken Mathews